JP2016526039A5 - - Google Patents

Download PDF

Info

Publication number
JP2016526039A5
JP2016526039A5 JP2016515111A JP2016515111A JP2016526039A5 JP 2016526039 A5 JP2016526039 A5 JP 2016526039A5 JP 2016515111 A JP2016515111 A JP 2016515111A JP 2016515111 A JP2016515111 A JP 2016515111A JP 2016526039 A5 JP2016526039 A5 JP 2016526039A5
Authority
JP
Japan
Prior art keywords
dexamethasone
unit dose
single unit
days
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016515111A
Other languages
English (en)
Japanese (ja)
Other versions
JP6530744B2 (ja
JP2016526039A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/039319 external-priority patent/WO2014190248A1/en
Publication of JP2016526039A publication Critical patent/JP2016526039A/ja
Publication of JP2016526039A5 publication Critical patent/JP2016526039A5/ja
Application granted granted Critical
Publication of JP6530744B2 publication Critical patent/JP6530744B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016515111A 2013-05-24 2014-05-23 白内障手術後の炎症における徐放性デキサメタゾンの使用 Active JP6530744B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827091P 2013-05-24 2013-05-24
US61/827,091 2013-05-24
PCT/US2014/039319 WO2014190248A1 (en) 2013-05-24 2014-05-23 Use of sustained release dexamethasone in post-cataract surgery inflammation

Publications (3)

Publication Number Publication Date
JP2016526039A JP2016526039A (ja) 2016-09-01
JP2016526039A5 true JP2016526039A5 (enExample) 2017-07-06
JP6530744B2 JP6530744B2 (ja) 2019-06-12

Family

ID=51934201

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016515111A Active JP6530744B2 (ja) 2013-05-24 2014-05-23 白内障手術後の炎症における徐放性デキサメタゾンの使用

Country Status (9)

Country Link
US (4) US10028965B2 (enExample)
EP (2) EP4082525A1 (enExample)
JP (1) JP6530744B2 (enExample)
KR (1) KR102245354B1 (enExample)
CN (2) CN105407896B (enExample)
AU (1) AU2014268434B2 (enExample)
CA (1) CA2913336C (enExample)
ES (1) ES2902951T3 (enExample)
WO (1) WO2014190248A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103648544B (zh) 2011-04-25 2017-03-22 爱康生物科技有限公司 用于注射器的剂量引导件
EP3302382A4 (en) 2015-05-29 2019-02-20 Allergan, Inc. IMPLANT FOR THE TREATMENT OF OCULAR DISEASE
EP3478285A4 (en) 2016-06-30 2020-07-22 Durect Corporation DEPOSIT FORMULATIONS
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
CN111757764B (zh) 2018-02-09 2022-09-06 爱康生物科学股份有限公司 用于从注射器装载和输送小体积剂量的系统、套件和方法
WO2020168106A1 (en) 2019-02-13 2020-08-20 Notable Labs, Inc. Combinations of agonists of protein kinase c with steroids or retinoic acids for the treatment of cancer
IT201900003529A1 (it) * 2019-03-11 2020-09-11 Ntc S R L Riduzione della posologia antibiotica in composizioni antibiotico/antinfiammatorio in associazione tra loro per uso oftalmico
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11974979B2 (en) 2022-01-29 2024-05-07 Resurge Therapeutics, Inc. Treatments for benign prostatic hyperplasia

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211793A (en) 1979-03-19 1980-07-08 American Cyanamid Company Triethyl citrate solutions of PGE-type compounds
DE3500103C2 (de) 1985-01-04 1987-01-22 R.P. Scherer GmbH, 6930 Eberbach Pharmazeutische Zubereitung mit einem in Wasser und Verdauungssäften schwer löslichen Wirkstoff
US4889845A (en) 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
JP2895234B2 (ja) 1992-11-09 1999-05-24 クエスト・インターナショナル・ビー・ブイ 可溶化剤
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US20040024006A1 (en) 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030216303A1 (en) 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
JP2004511431A (ja) 2000-06-28 2004-04-15 アトゥル・ジェイ・シュクラ 生物活性物質を含む生分解性ビヒクルおよび送達システム
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6960346B2 (en) 2002-05-09 2005-11-01 University Of Tennessee Research Foundation Vehicles for delivery of biologically active substances
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
ITMI20032087A1 (it) 2003-10-27 2005-04-28 Pharmafilm S R L Film autosupportanti per uso farmaceutico ed alimentare.
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
WO2006039336A2 (en) 2004-10-01 2006-04-13 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
EP2266638A3 (de) 2009-06-25 2014-08-13 Biotronik VI Patent AG Biokorrodierbares Implantat mit einer aktiven Beschichtung
US20110160645A1 (en) 2009-12-31 2011-06-30 Boston Scientific Scimed, Inc. Cryo Activated Drug Delivery and Cutting Balloons
CN103648544B (zh) * 2011-04-25 2017-03-22 爱康生物科技有限公司 用于注射器的剂量引导件
WO2013058838A2 (en) * 2011-06-10 2013-04-25 Wong Vernon G Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer
RS60051B1 (sr) * 2011-06-10 2020-04-30 Ramscor Inc Formulacije sa produženim oslobađanjem za isporuku proteina u oko i postupci njihove pripreme
US20160095818A1 (en) 2013-06-03 2016-04-07 Mcneil Ab Solid pharmaceutical dosage form for release of at least one active pharmaceutical ingredient in the oral cavity

Similar Documents

Publication Publication Date Title
JP2016526039A5 (enExample)
TWI705820B (zh) Gip/glp1促效劑組合物
JP5882993B2 (ja) 抗精神病薬デポ型注射用組成物
JP6896015B2 (ja) 注射速度が増大したアリピプラゾール調合物
AR064078A1 (es) Sistema de administracion de farmacos intraocular inyectable biocompatible, su uso para preparar un medicamento y proceso para su preparacion
KR102055937B1 (ko) 불용성 코르티코스테로이드 및 수용성 코르티코스테로이드를 포함하는 약학적 제형
JP2010511596A5 (enExample)
BRPI0909630B1 (pt) Composição em suspensão aquosa particularmente adequada para injeção dentro do olho
AR081575A1 (es) Formas de dosificacion oral de bendamustina y su uso terapeutico
ES2902951T3 (es) Uso de dexametasona de liberación sostenida en la inflamación después de cirugía de cataratas
EA029921B1 (ru) Депо-композиция палиперидона с замедленным высвобождением, способ ее получения и способ психиатрического лечения с использованием этой композиции
JP2013535422A5 (enExample)
RU2015109296A (ru) Системы доставки лекарственного средства и способы лечения рака мочевого пузыря, включающие применение оксалиплатина
JP2011517311A (ja) 麻酔薬組成物、製剤及び使用方法
JP2018522920A5 (enExample)
CN103705910B (zh) 一种齐考诺肽注射型皮下植入剂及其制备方法
CN103877005A (zh) 一种复方奥氮平皮下埋植缓释剂
WO2017013677A1 (en) Stable liquid injectable solution of midazolam and pentazocine
CN100379420C (zh) 一种用于戒毒的长效缓释制剂及其制备方法和用途
RU2581022C1 (ru) Противоопухолевые фармацевтические композиции и способ лечения рака молочной железы
CA2994748C (en) Pharmaceutical composition comprising sumatripan for treating migraine
CN101416912B (zh) 一种止血产品
CN103877004A (zh) 一种复方利培酮皮下埋植缓释剂及其制备方法
CN108309932A (zh) 一种肌肉注射用青蒿琥酯的溶剂
CN208003121U (zh) 一种可稳定持续释放纳米药物的存储单元